Skip to content
10-Q

Quarterly Report

RHYTHM PHARMACEUTICALS, INC. RYTM

0001628280-26-030549

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 68.53M sh
Shares Diluted Q1 2026 · Mar 31, 2026 67.97M sh
Shares Diluted Q1 2026 · Mar 31, 2025 63.06M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$44.19M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$40.35M
Long Term Debt Q1 2026 · Mar 31, 2026 $98.34M
Long Term Debt Q1 2026 · Dec 31, 2025 $100.89M
Short Term Debt Q1 2026 · Mar 31, 2026 $10.13M
Short Term Debt Q1 2026 · Dec 31, 2025 $7.3M
Short Term Investments Q1 2026 · Mar 31, 2026 $278.49M
Short Term Investments Q1 2026 · Dec 31, 2025 $334.65M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $62.14M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $54.3M
Stockholders Equity Q1 2026 · Mar 31, 2026 $122.91M
Stockholders Equity Q1 2026 · Dec 31, 2025 $139.07M
Stockholders Equity Q1 2026 · Mar 31, 2025 $18.95M
Stockholders Equity Q1 2026 · Dec 31, 2024 $21.73M
Current Liabilities Q1 2026 · Mar 31, 2026 $103.2M
Current Liabilities Q1 2026 · Dec 31, 2025 $105.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $204.7M
Total Liabilities Q1 2026 · Dec 31, 2025 $210.17M
Current Assets Q1 2026 · Mar 31, 2026 $430.09M
Current Assets Q1 2026 · Dec 31, 2025 $466.92M
Total Assets Q1 2026 · Mar 31, 2026 $442.32M
Total Assets Q1 2026 · Dec 31, 2025 $480.2M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.83
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.81
Eps Basic Q1 2026 · Mar 31, 2026 −$0.83
Eps Basic Q1 2026 · Mar 31, 2025 −$0.81
Sga Expense Q1 2026 · Mar 31, 2026 $63.59M
Sga Expense Q1 2026 · Mar 31, 2025 $39.09M
Rd Expense Q1 2026 · Mar 31, 2026 $41.73M
Rd Expense Q1 2026 · Mar 31, 2025 $36.97M
Net Income Q1 2026 · Mar 31, 2026 −$55.64M
Net Income Q1 2026 · Mar 31, 2025 −$49.5M
Operating Income Q1 2026 · Mar 31, 2026 −$52.36M
Operating Income Q1 2026 · Mar 31, 2025 −$47M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $7.16M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $3.65M
Revenue Q1 2026 · Mar 31, 2026 $60.11M
Revenue Q1 2026 · Mar 31, 2025 $32.7M